ProfileGDS5678 / 1439956_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 94% 93% 97% 93% 95% 93% 93% 94% 91% 91% 93% 91% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.0109494
GSM967853U87-EV human glioblastoma xenograft - Control 28.3090994
GSM967854U87-EV human glioblastoma xenograft - Control 38.0302693
GSM967855U87-EV human glioblastoma xenograft - Control 49.4427497
GSM967856U87-EV human glioblastoma xenograft - Control 57.9544893
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.237995
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.686393
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.9412193
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.9668694
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.5147791
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.4749191
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9289393
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.4656791
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.8794293